1. Home
  2. LQDA vs VAC Comparison

LQDA vs VAC Comparison

Compare LQDA & VAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • VAC
  • Stock Information
  • Founded
  • LQDA 2004
  • VAC 1984
  • Country
  • LQDA United States
  • VAC United States
  • Employees
  • LQDA N/A
  • VAC N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • VAC Real Estate
  • Sector
  • LQDA Health Care
  • VAC Finance
  • Exchange
  • LQDA Nasdaq
  • VAC Nasdaq
  • Market Cap
  • LQDA 2.5B
  • VAC 2.6B
  • IPO Year
  • LQDA 2018
  • VAC N/A
  • Fundamental
  • Price
  • LQDA $25.00
  • VAC $75.76
  • Analyst Decision
  • LQDA Strong Buy
  • VAC Buy
  • Analyst Count
  • LQDA 9
  • VAC 6
  • Target Price
  • LQDA $32.11
  • VAC $90.50
  • AVG Volume (30 Days)
  • LQDA 2.2M
  • VAC 334.0K
  • Earning Date
  • LQDA 11-12-2025
  • VAC 11-05-2025
  • Dividend Yield
  • LQDA N/A
  • VAC 4.06%
  • EPS Growth
  • LQDA N/A
  • VAC 57.22
  • EPS
  • LQDA N/A
  • VAC 6.65
  • Revenue
  • LQDA $19,322,000.00
  • VAC $3,378,000,000.00
  • Revenue This Year
  • LQDA $405.58
  • VAC $56.47
  • Revenue Next Year
  • LQDA $373.93
  • VAC $3.53
  • P/E Ratio
  • LQDA N/A
  • VAC $11.71
  • Revenue Growth
  • LQDA 30.20
  • VAC 8.79
  • 52 Week Low
  • LQDA $9.68
  • VAC $49.22
  • 52 Week High
  • LQDA $29.94
  • VAC $100.32
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 45.82
  • VAC 46.04
  • Support Level
  • LQDA $25.34
  • VAC $75.84
  • Resistance Level
  • LQDA $28.00
  • VAC $79.56
  • Average True Range (ATR)
  • LQDA 1.32
  • VAC 2.31
  • MACD
  • LQDA -0.70
  • VAC -0.20
  • Stochastic Oscillator
  • LQDA 0.50
  • VAC 12.86

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About VAC Marriott Vacations Worldwide Corporation

Marriott Vacations Worldwide Corp functions in the United States leisure industry. It owns and manages a cluster of resorts and accommodation facilities under trademarks like Marriott Vacation Club, Grand Residencies, and The Ritz-Carlton Destination Club predominantly in the United States. Some of its properties are also spread across Europe and Asia Pacific. Marriott's majority revenue components include the sale of vacation ownership products such as luxurious vacation packages. In addition, it offers purchase money financing to the end users of its core services. The company operates in two reportable segments: Vacation Ownership and Exchange & Third-Party Management. The majority of revenue is derived from the Vacation Ownership segment.

Share on Social Networks: